New antibody injection targets advanced cancers in early human trial
NCT ID NCT06609187
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase study tests a new drug called GNC-077 in 20 adults with advanced breast cancer or other solid tumors that have spread. The main goals are to check safety, find the best dose, and see if the drug can shrink tumors. Participants receive the drug by injection, and researchers monitor side effects and how the body processes the medication.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital Chinese Academy of Medical Sciences
RECRUITINGBeijing, Beijing Municipality, China
Contact
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- A dab of gel on the breathing tube might spare surgery patients a sore throat — a trial puts it to the test.
- Can a deeper nerve block ease pain after breast surgery?
- Does breast cancer radiation harm a key immune gland? a study investigates
- A web program may ease the emotional toll of chemotherapy hair loss
- Can 3D breast imaging spot more dangerous cancers than standard mammograms?